Panda Ashok Kumar, Kar Sarbeswar, Rai Amit Kumar, Rao B C S, Srikanth N
Central Ayurveda Research Institute, Bhubaneswar, Odisha, Central Council of Research in Ayurveda Sciences, Ministry of AYUSH, Govt. of India, India.
JSS Ayurveda Medical College &Hospital, Mysore, Karnataka, India.
J Ayurveda Integr Med. 2022 Apr-Jun;13(2):100538. doi: 10.1016/j.jaim.2021.100538. Epub 2022 Jan 4.
Corona Virus disease (COVID-19) has become a global pandemic resulting in large scale morbidity and mortality worldwide. The management of COVID-19 has been a big challenge because of multifactorial pathophysiology and no specific treatment. AYUSH-64, a poly-herbal formulation developed by CCRAS, Ministry of AYUSH, Govt. of India through extensive pharmacological, toxicological and clinical studies has proven its safety and efficacy in infective febrile conditions such as malaria and influenza. AYUSH- 64 has four ingredients having immunomodulatory, anti-inflammatory, antipyretic, antioxidant and anti-viral activities. It arrests the extreme inflammatory responses in COVID-19 that causes progression to significant morbidity. AYUSH-64 has also been incorporated in the National COVID management protocol based on Ayurveda and Yoga by Government of India for asymptomatic and mild cases of COVID-19. Further, on the basis of tangible evidence generated through robust clinical and experimental studies on AYUSH-64, the Ministry of AYUSH has launched nation-wide campaign for mass distribution of AYUSH-64 to asymptomatic, mild to moderate COVID-19 patients in home isolation to reduce the burden on the hospital. This review will highlight the specifications of AYUSH-64, its mechanism of action, its repurposing for COVID-19, various clinical and experimental studies.
冠状病毒病（COVID-19）已成为全球大流行疾病，在全球范围内导致大规模发病和死亡。由于其多因素病理生理学特点且缺乏特效治疗方法，COVID-19的管理一直是一项巨大挑战。印度政府阿育吠陀部下属的中央阿育吠陀研究所（CCRAS）研发的一种多草药配方——AYUSH-64，通过广泛的药理学、毒理学和临床研究，已证明其在疟疾和流感等感染性发热疾病中的安全性和有效性。AYUSH-64含有四种具有免疫调节、抗炎、解热、抗氧化和抗病毒活性的成分。它能抑制COVID-19中导致病情进展至严重发病的极端炎症反应。AYUSH-64还被纳入了印度政府基于阿育吠陀和瑜伽制定的针对COVID-19无症状和轻症病例的国家管理方案。此外，基于对AYUSH-64进行的有力临床和实验研究产生的确凿证据，阿育吠陀部发起了一项全国性运动，向居家隔离的COVID-19无症状、轻症至中症患者大规模分发AYUSH-64，以减轻医院负担。本综述将重点介绍AYUSH-64的规格、作用机制、其在COVID-19治疗中的重新应用、各种临床和实验研究。
